---
marp: true
paginate: true
footer: "PHA 548 | Sedativeâ€“Hypnotic Medicinal Chemistry | Lecture 1"
style: |
  section { font-family: 'Helvetica', sans-serif; text-align: left; padding: 45px; }
  h1 { font-size: 42px; }
  h2 { font-size: 32px; margin-bottom: 10px; }
  h3 { font-size: 26px; }
  p, li { font-size: 22px; line-height: 1.25; }
  table { font-size: 20px; width: 100%; }
  img { max-width: 100%; height: auto; margin-top: 10px; margin-bottom: 10px; }
---

# ğŸ§¬ Medicinal Chemistry of Benzodiazepine Sedative-Hypnotics

**Course:** PHA 548 â€” Pharmacology & Medicinal Chemistry  
**Instructor:** Dr. Sidney Bolden, Jr.  
**Time:** 75â€“90 minutes | **Lecture 1**

---

## ğŸ¯ Learning Objectives (ACPE-aligned)

By the end of this lecture, students will be able to:

1ï¸âƒ£ Describe the benzodiazepine binding site and MOA at the **GABAA Î±â€“Î³ interface** *(Bloom: Understand)*  
2ï¸âƒ£ Apply **SAR principles** to predict potency & subtype preference *(Bloom: Apply)*  
3ï¸âƒ£ Predict **duration of action** based on structural and metabolic features *(Bloom: Analyze)*  
4ï¸âƒ£ Evaluate the **design innovations** leading to remimazolam *(Bloom: Evaluate)*  

---

## CNS Target: GABAA Receptor

- Pentameric Clâ» channel (2Î± + 2Î² + 1Î³)  
- **BZD binding site**: Î±â€“Î³ subunit interface (distinct from GABA site)
- â†‘ frequency of GABA-dependent Clâ» channel openings
- **Do not** activate channel without GABA present

---

### Functional Subtype Selectivity

| Subunit | Primary Effect |
|--------|----------------|
| **Î±1** | Sedation, amnesia |
| **Î±2 / Î±3** | Anxiolysis, muscle relaxation |
| **Î±5** | Cognitive impairment |

---

## Required Benzodiazepine Pharmacophore

- **5-phenyl-1,4-benzodiazepin-2-one**
- Anchoring motifs:
  - **N1â€“C2 carbonyl** â†’ H-bonding
  - **Ring A** (C7â€“EWG) â†’ receptor affinity
  - **Ring C** planar phenyl â†’ Ï€-stacking

*(insert structure figure here)*

---

## High-Yield SAR â€” Part 1

| Site | MedChem Rule | Effect |
|------|--------------|-------|
| C7 (Ring A) | Electronegative (Cl/Br/NOâ‚‚) **required** | â†‘ affinity/potency |
| C5 phenyl (Ring C) | Must remain aromatic/planar | Required for agonism |
| C4â€² para | Bulky substituent ğŸ›‘ | Steric block â†’ â†“/no activity |

---

## High-Yield SAR â€” Part 2 â€” PK Drivers

| Feature | Structural Basis | PK Result |
|--------|-----------------|----------|
| 3-OH | â†‘ Phase II glucuronidation | Shorter duration |
| Triazolo/Imidazo fusion | Metabolic shielding | â†‘ potency, â†“ active metabolites |
| N-alkyl + lipophilic | Requires Phase I oxidation | Long-acting metabolites |
| **Ester side chain** | **Soft-drug design** | Ultra-short duration (remimazolam) |

---

## PK & Duration: Structure â†’ Metabolism â†’ Action

*(insert table_12.2.jpg visual here)*

---

## Metabolism Examples

Temazepam â†’ direct glucuronidation â†’ short duration  
Flurazepam â†’ CYP3A4 N-dealkylation â†’ active metabolites â†’ long duration  
Remimazolam â†’ esterase hydrolysis â†’ ultra-short

*(insert diagram figures)*

---

## Ultra-Short Soft Drug: Remimazolam

- IV procedural sedation (<30 min procedures)
- Esterase hydrolysis â†’ inactive carboxylic metabolite
- Minimal CYP involvement
- Rapid recovery

*(insert Remimazolam figure)*

---

## Clinical MedChem Implications

| Drug | Avoid In | Prefer In |
|-----|----------|-----------|
| Flurazepam | Elderly; fall risk | None |
| Temazepam | â€” | Liver impairment patients |
| Triazolam | Patients prone to amnesia | Sleep onset insomnia |
| Remimazolam | Routine chronic use | Short procedures, anesthetic adjunct |

High-value **NAPLEX reasoning**.

---

## Active Learning â€” Pick the Best Design

Which modification **shortens duration of action**?

A) Add N-alkyl chain  
B) Add **3-OH group**  
C) Add bulky 4â€² substitution  
D) Add fused triazolo ring  

âœ” Correct: **B**  
ğŸ’¡ Because Phase II conjugation dominates

---

## Summary Slide

BZD **structure determines duration**:

- Soft drug â†’ **ester â†’ hydrolysis â†’ ultra-short**
- 3-OH â†’ **glucuronidation â†’ short/intermediate**
- Oxidation + active metabolites â†’ **long duration**

BZDs require **GABA** â†’ safety advantage vs barbiturates

---

# Questions?

